Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 4:26 PM
Ignite Modification Date: 2025-12-24 @ 4:26 PM
NCT ID: NCT06072066
Eligibility Criteria: Inclusion Criteria: * Males and females 30 to 70 years of age * The presence of mild to moderate rosacea (erythematotelangiectatic or papulopustular) * High sensitivity C-reactive protein (hs-CRP) that is greater than or equal to 1.0 mg/L Exclusion Criteria: * The presence of severe rosacea as noted by the investigator global assessment. * Those who are unwilling to discontinue oral supplementation, or supplement ingredients found in the study's oral product 1 month prior to enrollment. * Discontinuation of oral L-glutamine or L-glutamine containing supplement 1 month prior to enrollment * Those who are unwilling to discontinue topical benzoyl peroxide or retinoids for 2 weeks prior to enrollment. * Those who are unwilling to keep their facial regimen the same throughout the study. * Individuals who have been on an oral antibiotic within the previous one month. * Individuals who are pregnant or breastfeeding. * Individuals who have changed any of their hormonal based contraception or therapies within 3 months prior to joining the study. * Individuals on oral contraceptive pills or progesterone or estrogen containing therapies. * Use of isotretinoin within the three months prior to enrollment. * Individuals on finasteride or dutasteride * Current tobacco smoker, smoker within the past year, or greater than 5 pack-year tobacco smoking history.
Healthy Volunteers: True
Sex: ALL
Minimum Age: 30 Years
Maximum Age: 70 Years
Study: NCT06072066
Study Brief:
Protocol Section: NCT06072066